Key Highlights
- 7.34% is the indicated pre-market decline for Neogen Corporation (NASDAQ:NEOG) on November 18, 2026, to USD 10.10 from a calculated prior close of USD 10.90, a calculated loss of USD 0.80 per share.
- 222.8 million USD was quarterly Revenue at Neogen Corporation (NASDAQ:NEOG), up 6.5% year over year with core growth of 8.1%, ahead of the USD 208.3 million analyst estimate in published coverage.
- 887.5 million USD is the raised full-year revenue guidance midpoint, alongside an adjusted EBITDA midpoint of USD 182 million, after adjusted Net Income of USD 17.5 million and adjusted EPS of USD 0.08.
- 13.98 USD was the September 2026 52-week high, and the indicated price of USD 10.10 sits about 27.8% below it (calculated), after an FDA warning letter on the HYCOAT veterinary product.
What Moved Neogen Corporation (NASDAQ:NEOG) in Pre-Market Trading on November 18, 2026 (-USD 0.80, -7.34%)
Neogen Corporation (NASDAQ:NEOG) is indicated at USD 10.10 in pre-market trading on November 18, 2026, a pre-market move of -7.34%. The calculated prior close, meaning the November 17, 2026 regular-session close, is USD 10.90 (USD 10.10 divided by 0.9266), and the calculated USD move is -USD 0.80 (price minus prior close). A corroborated market Capitalization and pre-market Volume were not available, so neither is stated.
The Rationale: No Fresh Catalyst After the FDA Letter and Raised Outlook for Neogen Corporation (NASDAQ:NEOG)
No catalyst dated November 18, 2026 was identified in published coverage. The most recent identified company news is the October 7, 2026 update, when shares jumped 14.1% in pre-market trading after revenue of USD 222.8 million and a raised full-year outlook. The chief financial officer said about 300 basis points of core growth came from customer order timing and distributor inventory comparisons, and indicator testing and Petrifilm sales rose 11%. The chief executive said the first Petrifilm kit was fully validated ahead of a planned Manufacturing transfer to Lansing in November. About eight days earlier, an FDA warning letter citing fungal contamination in the HYCOAT veterinary product drew a 5.4% drop. As general context, shares that have rallied strongly can give back gains without fresh news.
Valuation, Liquidity and Risks for Neogen Corporation (NASDAQ:NEOG)
Shares were up 68.1% year to date as of October 7, 2026, when they closed near USD 11.79 against the USD 13.98 high. Adjusted net income of USD 17.5 million on revenue of USD 222.8 million implies an adjusted Margin of about 7.9% (calculated). The guidance midpoint of USD 887.5 million and adjusted EBITDA midpoint of USD 182 million imply an adjusted EBITDA margin of about 20.5% (calculated). Market capitalization, cash, Debt and share count could not be corroborated. Risks include regulatory action on veterinary products, the manufacturing transfer, order timing effects and the Volatility that follows a large rally.
Where Things Stand
Neogen Corporation (NASDAQ:NEOG) is indicated at USD 10.10 before the November 18, 2026 open, a pre-market move of -7.34% and a calculated loss of USD 0.80 from a calculated prior close of USD 10.90. No catalyst dated today was identified in published coverage. Context includes quarterly revenue of USD 222.8 million, a raised full-year revenue guidance midpoint of USD 887.5 million, an adjusted EBITDA midpoint of USD 182 million and the FDA warning letter on HYCOAT. The planned Petrifilm manufacturing transfer to Lansing in November 2026 and a stock still up for the year are further context. Regulatory, execution and volatility risks remain, and this is information only, not Investment advice.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...